Medindia

X

Colon Cancer Pipeline Market 2016 Review Report Covering Therapeutics Development

Monday, July 18, 2016 Cancer News J E 4
Advertisement

PUNE, India, July 18, 2016 /PRNewswire/ --

ReportsnReports.com adds "Colon Cancer - Pipeline Review, H1 2016" to its store providing an overview of the Colon Cancer's therapeutic pipeline complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Colon Cancer with 180 market data tables and 16 figures, spread across 672 pages is available at http://www.reportsnreports.com/reports/622294-colon-cancer-pipeline-review-h1-2016.html .

Companies discussed in this Colon Cancer Pipeline Review, H1 2016 report include ACF Pharmaceuticals, LLC, Adgero Biopharmaceuticals, Inc., Aduro BioTech, Inc., Advanced Proteome Therapeutics Corporation, Advenchen Laboratories, LLC, Agenus, Inc., AGV Discovery, SAS, AIMM Therapeutics B.V., Ambrx, Inc., Anavex Life Sciences Corp., AndroScience Corporation, Aphios Corporation, Aposense Ltd., Aptose Biosciences Inc., Asana BioSciences, LLC, AstraZeneca Plc, Aurigene Discovery Technologies Limited, BCN Biosciences L.L.C., Bio-Path Holdings, Inc., Biogazelle, Bioncotech Therapeutics S.L., Blirt S.A., Boehringer Ingelheim GmbH, Can-Fite BioPharma Ltd., Celprogen, Inc., Celyad SA, Chiome Bioscience, Inc., Critical Outcome Technologies Inc., Cyclacel Pharmaceuticals, Inc., CytomX Therapeutics, Inc., Cytune Pharma SAS, CZ BioMed Corp, DEKK-TEC, Inc., Digna Biotech, S.L., Eli Lilly and Company, EntreChem, S.L., EnzymeBioSystems, F. Hoffmann-La Roche Ltd., GlycaNova Norway AS, Halozyme Therapeutics, Inc., Heat Biologics, Inc., Helix BioPharma Corp., Histogen, Inc., Horizon Pharma Plc, Huperion Sarl, Idera Pharmaceuticals, Inc., Ignyta, Inc., Immunome Inc., Immunomedics, Inc., Immunotope, Inc., Immupharma Plc, IMPACT Therapeutics, Inc., Incuron, LLC, Infinity Pharmaceuticals, Inc., Inflection Biosciences Limited, Innopharmax Inc., Intezyne, Inc, Ironwood Pharmaceuticals, Inc., Jasco Pharmaceuticals, LLC., Jiangsu Kanion Pharmaceutical Co., Ltd., JW Pharmaceutical Corporation, Karyopharm Therapeutics, Inc., Kyowa Hakko Kirin Co., Ltd., Les Laboratoires Servier SAS, Lipocure Ltd., LipoMedix Pharmaceutical Inc., Lupin Limited, Lymphocyte Activation Technologies, S.A., MabVax Therapeutics Holdings, Inc., MacroGenics, Inc., MaxiVAX SA, Meabco A/S, Molecular Targeting Technologies, Inc., MolMed S.p.A., Monopar Therapeutics LLC, Multimmune GmbH, NormOxys, Inc., Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., OncoVista Innovative Therapies, Inc., Ono Pharmaceutical Co., Ltd., Orega Biotech SAS, OSE Immunotherapeutics, Panacea Pharmaceuticals, Inc., PharmaCyte Biotech, Inc., Pharminox Limited, Philogen S.p.A., Pique Therapeutics, Plexxikon Inc., Provecs Medical GmbH, Provectus Biopharmaceuticals, Inc., Qu Biologics Inc., Regeneron Pharmaceuticals, Inc., Rexahn Pharmaceuticals, Inc., Rgenix, Inc., Sareum Holdings Plc, Savoy Pharmaceuticals, Inc., Sellas Inc., Sigma-Tau S.p.A., Sirnaomics, Inc., Somantix B.V., Sorrento Therapeutics, Inc., Sphaera Pharma Pvt. Ltd., Starpharma Holdings Limited, Synergys Biotherapeutics, Inc.,Synta Pharmaceuticals Corp., Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited, Theryte Limited, Transgene Biotek Limited, TVAX Biomedical, Inc., Tyg Oncology Ltd., Vaccinogen, Inc., Vault Pharma Inc., Vaximm AG, VG Life Sciences, Inc., Yakult Honsha Co., Ltd., Zensun (Shanghai) Sci & Tech Co., Ltd. and ZIOPHARM Oncology, Inc.

Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=622294 .

Colon Cancer Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.  

Colon Cancer pipeline therapeutics constitutes close to 260 molecules. Out of which approximately 197 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 25, 3, 148, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 42 and 16 molecules, respectively.

Another newly published market research report titled on Peptic Ulcers - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Peptic Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peptic Ulcers and special features on late-stage and discontinued projects. Companies discussed in this research are Ache Laboratorios Farmaceuticos S/A, Astellas Pharma Inc., ChoDang Pharm Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Kukje Pharmaceutical Industry Co., Ltd., RaQualia Pharma Inc., Sequella, Inc., Sihuan Pharmaceutical Holdings Group Ltd., Sinil Pharmaceutical Co., Ltd and Yooyoung Pharmaceutical Co., Ltd. Peptic Ulcers Pipeline market research report of 57 pages is available at http://www.reportsnreports.com/reports/622307-peptic-ulcers-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:   

Facebook: https://www.facebook.com/ReportsnReports/ LinkedIn: https://www.linkedin.com/company/reportsnreports Twitter:  https://twitter.com/marketsreports G+ / Google Plus: https://plus.google.com/111656568937629536321/posts RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml

Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. +1 888 391 5441 sales@reportsandreports.com

SOURCE ReportsnReports

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Assisi Animal Health Highlights Some Best Practice...
S
Merck Receives European Medicines Agency Acceptanc...